Dogwood Therapeutics Presents Halneuron® Program at Annual Summit

Dogwood Therapeutics, Inc. (Nasdaq: DWTX), a development-stage biotechnology company, has announced that its Chief Medical Officer will present an overview of the Halneuron® pain management program at the 19th Annual Pain Therapeutics Summit. The presentation will provide insights into the use of Halneuron®, a highly purified form of tetrodotoxin, in treating Chemotherapy Induced Neuropathic Pain (CINP).

Current research emphasizes Halneuron®'s efficacy as a Nav 1.7 sodium channel modulator, crucial for pain transmission. Recent preclinical trials in rats showed that Halneuron® significantly suppressed pain, comparable to or greater than Nav 1.8 modulator, VX-548. A combination of the two did not display additional synergy.

Halneuron® is currently undergoing a Phase 2b clinical trial in the U.S. to evaluate its safety and effectiveness in treating CINP. Interim results are anticipated by the end of 2025.